1964
DOI: 10.1007/bf02953856
|View full text |Cite
|
Sign up to set email alerts
|

The treatment of iron overload with desferrioxamine B

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
4
0

Year Published

1965
1965
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 10 publications
1
4
0
Order By: Relevance
“…Previous investigations have indicated that the thickness of the anodized oxide film was proportional to the forming potential. 7,[29][30][31][32] This relationship has been confirmed in this investigation except that two different stages were observed. At a low forming voltage, amorphous oxide was formed at a relatively higher rate per increase in forming voltage.…”
Section: Resultssupporting
confidence: 83%
“…Previous investigations have indicated that the thickness of the anodized oxide film was proportional to the forming potential. 7,[29][30][31][32] This relationship has been confirmed in this investigation except that two different stages were observed. At a low forming voltage, amorphous oxide was formed at a relatively higher rate per increase in forming voltage.…”
Section: Resultssupporting
confidence: 83%
“…A range of structurally diverse microbial natural products contain one or more hydroxamate functional groups (figure 1), which are employed as metal ion chelators to inhibit or enable important biological processes [1]. Prominent examples include trichostatin A (2), a histone deacetylase (HDAC) inhibitor with anti-cancer activity that is widely used in epigenetics research [2], and desferrioxamine B (7), which is marketed as desferral for the treatment of iron overload and neuroblastoma in humans [3,4]. Trichostatin A blocks histone deacetylation via chelation of its hydroxamate group to the active zinc(II) ion of HDACs [5], whereas desferrioxamine B uses its three hydroxamate groups to sequester ferric iron via formation of a hexadentate complex [6].…”
Section: Introductionmentioning
confidence: 99%
“…During this section we will focus mainly in how siderophores can be used or applied to treat different diseases or help to develop diagnostic tests to improve human health, among other approaches. The first and most studied aspect of siderophore biotechnology is the treatment of iron overload during transfusion due to non-hemorrhagic conditions (34,66). Desferrioxamine B, a siderophore produced by the bacteria Streptomyces pilosus, has been used in different cases of iron poisoning, or overload, confirming its biotechnological potential (17).…”
Section: Pharmacological and Medical Applicationsmentioning
confidence: 99%